Fludarabine
Antimetabolite
DB01073
Approved Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
3
Targets
0
Resistance Mutations
3
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
Details
DrugBank ID
DB01073 ↗
Approval Date
2003-09-12
Molecular Weight
285.235 g/mol
Drug Class
Antimetabolite
ATC Codes
L01BB05
Synonyms
2-F-ARAA, 2-fluoro ARA-A
PubChem
CID: 657237 ↗
ChEMBL
CHEMBL1568 ↗
SMILES
NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
ADMET Profile
Computing properties…
Drug References (DrugBank)